Skip directly to content

Medical and Educational Goods and Services (MEGS)

We are committed to supporting healthcare and research organisations to drive improvements in patient care and help achieve the best results for patients and the NHS.

One of the ways in which we do this is by providing Medical and Educational Goods and Services (MEGS) to organisations that are comprised of health professionals and / or provide healthcare or conduct research. 

The MEGS that we provide are in the form of financial grants or services delivered by a Pfizer colleague or a 3rd party supplier engaged by Pfizer. MEGS are intended to either enhance patient care or benefit the NHS and maintain patient care. MEGS cannot be linked to prescribing or use of a specific medicine. Pfizer’s involvement is strictly limited to the provision or delivery of the MEGS grant or service and we do not receive any direct benefit in return. MEGS do not constitute an inducement to prescribe, supply, administer, recommend, buy or sell any medicine.

Information on MEGS is contained within the ABPI Code of Practice and can be explored in interactive form on the Prescription Medicines Code of Practice Authority (PMCPA) website.

Each year we publish details of all of the organisations that we have supported with a MEGS along with details of the financial amount provided and a description of the service provided if applicable.

For more details see our Medical and Educational Goods and Services (MEGS) grants reports

 

Requesting Pfizer Medical and Educational Goods and Services

Listed below are the MEGS that we are currently making available to Healthcare Organisations. Dependent on the nature of the MEGS, some are available through a competitive review process and others on a 'first come, first served' basis. Both types are subject to any stated criteria and available capacity:

If you are interested in obtaining support for your own bespoke project, use our enquiry form and select the option 'Bespoke project with support from Pfizer' option to request a meeting with a Pfizer colleague to discuss your proposal.

PP-PFE-GBR-0637 / Sept 2017